Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.

@article{Kudoh2011EffectsOB,
  title={Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.},
  author={Kazuya Kudoh and Masashi Takano and Hiroko Kouta and Ryoko Kikuchi and Tsunekazu Kita and Morikazu Miyamoto and Akio Watanabe and Masafumi Kato and Tomoko Goto and Yoshihiro Kikuchi},
  journal={Gynecologic oncology},
  year={2011},
  volume={122 2},
  pages={233-7}
}
OBJECTIVES Currently, pegylated liposomal doxorubicin (PLD) is regarded as one of the standard treatment options in recurrent ovarian cancers (ROC). Bevacizumab has shown significant antitumor activity for ROC in single-agent or in combination with cytotoxic agents. We have conducted a preliminary study to investigate effects of combination of bevacizumab and PLD for heavily pretreated patients with ROC. METHODS Thirty patients with ROC were treated with combination therapy with weekly… CONTINUE READING